S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
NASDAQ:SPRO

Spero Therapeutics - SPRO Stock Forecast, Price & News

$1.07
+0.17 (+18.89%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.88
$1.11
50-Day Range
$0.68
$1.16
52-Week Range
$0.68
$19.87
Volume
558,087 shs
Average Volume
421,067 shs
Market Capitalization
$37.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Spero Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
460.7% Upside
$6.00 Price Target
Short Interest
Healthy
1.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.80
Upright™ Environmental Score
News Sentiment
0.68mentions of Spero Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.58) to ($1.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

147th out of 1,122 stocks

Pharmaceutical Preparations Industry

57th out of 551 stocks

SPRO stock logo

About Spero Therapeutics (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Spero Therapeutics Trading Down 0.8 %

Shares of Spero Therapeutics stock opened at $0.90 on Wednesday. Spero Therapeutics has a twelve month low of $0.68 and a twelve month high of $19.87. The stock has a market capitalization of $31.43 million, a P/E ratio of -0.26 and a beta of 1.95. The business's fifty day moving average price is $0.84 and its 200 day moving average price is $4.40.

Spero Therapeutics (NASDAQ:SPRO - Get Rating) last issued its earnings results on Monday, May 16th. The company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.14). The firm had revenue of $2.07 million during the quarter, compared to analyst estimates of $2.85 million. Spero Therapeutics had a negative net margin of 1,147.64% and a negative return on equity of 151.75%. During the same quarter in the previous year, the business posted ($0.66) EPS. As a group, sell-side analysts predict that Spero Therapeutics will post -2.84 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Cantor Fitzgerald dropped their price target on Spero Therapeutics from $27.00 to $5.00 in a research report on Tuesday, May 17th. Berenberg Bank downgraded Spero Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, May 20th. Cowen downgraded Spero Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Wednesday, May 4th. Finally, HC Wainwright lowered their price objective on Spero Therapeutics from $10.00 to $7.00 and set a "buy" rating for the company in a research report on Monday.

Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SPRO Stock News Headlines

Spero Therapeutics (NASDAQ:SPRO) Price Target Cut to $7.00
The Women Who Shaped Short-Term Rental History
See More Headlines
Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SPRO Company Calendar

Last Earnings
11/10/2021
Today
8/18/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPRO
Fax
N/A
Employees
146
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+460.7%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-89,760,000.00
Net Margins
-1,147.64%
Pretax Margin
-1,147.64%

Debt

Sales & Book Value

Annual Sales
$18.26 million
Book Value
$1.02 per share

Miscellaneous

Free Float
33,538,000
Market Cap
$37.52 million
Optionable
Optionable
Beta
1.95

Key Executives

  • Dr. Ankit Mahadevia M.D. (Age 41)
    MBA, Co-Founder, Pres, CEO & Director
    Comp: $924.28k
  • Mr. Satyavrat Shukla C.F.A. (Age 50)
    CFO & Treasurer
    Comp: $788.84k
  • Ted Jenkins
    VP & Head of Investor Relations
  • Ms. Tamara Lynn Joseph L.L.M. (Age 59)
    Chief Legal Officer
  • Mr. James P. Brady
    Chief Human Resource Officer
  • Mr. Timothy Keutzer (Age 54)
    Chief Devel. Officer
  • Dr. Ian A. Critchley
    Head of Clinical Microbiology
  • Dr. Susannah Walpole Ph.D.
    Head of Clinical Operations
  • Dr. Angela Talley
    Sr. VP of Clinical Devel.













SPRO Stock - Frequently Asked Questions

Should I buy or sell Spero Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SPRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPRO, but not buy additional shares or sell existing shares.
View SPRO analyst ratings
or view top-rated stocks.

What is Spero Therapeutics' stock price forecast for 2022?

4 brokers have issued 1-year price targets for Spero Therapeutics' stock. Their SPRO share price forecasts range from $5.00 to $7.00. On average, they expect the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 460.7% from the stock's current price.
View analysts price targets for SPRO
or view top-rated stocks among Wall Street analysts.

How have SPRO shares performed in 2022?

Spero Therapeutics' stock was trading at $16.01 at the start of the year. Since then, SPRO stock has decreased by 93.3% and is now trading at $1.07.
View the best growth stocks for 2022 here
.

When is Spero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our SPRO earnings forecast
.

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by $0.04. The company had revenue of $3.06 million for the quarter, compared to analysts' expectations of $3 million. Spero Therapeutics had a negative trailing twelve-month return on equity of 151.75% and a negative net margin of 1,147.64%. During the same quarter in the prior year, the firm earned ($0.86) earnings per share.

What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?

27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.86%), Millennium Management LLC (0.96%), AQR Capital Management LLC (0.47%), Assenagon Asset Management S.A. (0.40%), State Street Corp (0.31%) and Northern Trust Corp (0.21%). Insiders that own company stock include Ankit Mahadevia, Aquilo Capital Management, Llc and Cristina Larkin.
View institutional ownership trends
.

How do I buy shares of Spero Therapeutics?

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $1.07.

How much money does Spero Therapeutics make?

Spero Therapeutics (NASDAQ:SPRO) has a market capitalization of $37.52 million and generates $18.26 million in revenue each year. The company earns $-89,760,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis.

How many employees does Spero Therapeutics have?

The company employs 146 workers across the globe.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The official website for the company is sperotherapeutics.com. The company can be reached via phone at (857) 242-1600 or via email at ir@sperotherapeutics.com.

This page (NASDAQ:SPRO) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.